Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort.

导出 LinkOut

翻译打印收藏纠错

作者： Hiroaki,Goto ^[1] ; Chitose,Ogawa ^[2] ; Hiroatsu,Iida ^[3] ; Keizo,Horibe ^[4] ; Iekuni,Oh ^[5] ; Satoru,Takada ^[6] ; Yoshinobu,Maeda ^[7] ; Hironobu,Minami ^[8] ; Yasuhiro,Nakashima ^[9] ; Joan D,Morris ^[10] ; William,Kormany ^[10] ; Yuqi,Chen ^[10] ; Toshihiro,Miyamoto ^[11]

作者单位： Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan. ^[1] Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[2] Division of Cell Therapy, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. ^[3] Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. ^[4] Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan. ^[5] Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan. ^[6] Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan. ^[7] Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan. ^[8] Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan. ^[9] Amgen Inc., Thousand Oaks, California, USA. ^[10] Department of Medicine and Biosystemic Science, University Graduate School of Medical Science, Fukuoka, Japan. ^[11]

关键词 Acute lymphoblastic leukemia Bispecific T-cell engager (BiTE?)Blinatumomab